Navigation Links
Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Date:6/16/2011

vering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes.  Activation of this important biological target protects against a broad range of diseases associated with inflammation and oxidative stress.  Reata is developing bardoxolone methyl, its lead product candidate, as the first therapy specifically intended to improve or preserve kidney function.

For more information please visit the company's Web site at www.reatapharma.com.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacturing and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
2. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
3. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
4. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
7. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
8. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
9. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
10. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
11. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:4/30/2015)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at ... $262.8 million at December 31, 2014. Our cash and ... a $100.0 million milestone payment received from AstraZeneca in ... in the U.S. "The recent U.S. launch ...
(Date:4/30/2015)... CARLSBAD, Calif. , April 30, 2015 /PRNewswire/ ... today it has earned a $10 million milestone ... an undisclosed target to treat a neurological disorder.  ... includes four drugs in development, under Isis, and ... novel therapies to treat neurological and neuromuscular disorders.  ...
Breaking Medicine Technology:Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen 2Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen 3
... BOSTON, Nov. 2 Schering-Plough Corporation (NYSE: SGP ... Phase IIa study of narlaprevir (SCH 900518), its investigational, ... patients with chronic hepatitis C virus (HCV) genotype 1. ... which patients received a 4-week lead-in of PEGINTRON(R) (peginterferon ...
... HCA has announced that Richard M. Bracken will become chairman ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20050825/CLTH069LOGO ) ... who will retire from the company, effective that same date. ... executive vice president, was elected to the board of directors, ...
Cached Medicine Technology:Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8Bracken to Become Chairman of HCA's Board of Directors Effective Dec. 15 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch ... latest and coolest technology products available to consumers. Scott Steinberg, ... review and shared with viewers how to protect their private ... is on computers and even more so online. It helps ... all over the world. In terms of work, the internet ...
(Date:5/3/2015)... 03, 2015 It is not too late to ... Walk in Memory of Lissa Anne Been in Arnold, Missouri ... great family-friendly event to honor her loving memory. It has benefited ... , Just having turned 37, Lissa suffered a brain aneurysm ... August 24, 2012. This event is designed to serve as a ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... We are pleased to announce the ... as one of the Top Workplaces of 2015. , ... treatment field for their ethics and standards of excellence. ... continue their educational efforts. The Delray Recovery Center prides ... their purpose – to help individuals heal from the ...
(Date:5/2/2015)... 2015 As a nonsurgical staple ... the face, neck and décolleté, radiofrequency energy is ... potential for the success of vulvovaginal rejuvenation. In ... Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory Board ... that ThermiGyn’s temperature controlled radio frequency, specifically that ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... Pharmaceuticals Inc. today,announced the appointment of Anthony "Tony" ... the recently initiated Phase 2 clinical trial of,CTS-1027 ... assisting in the,development of the longer-term clinical development ... more than 20 years in the,industry. Previous industrial ...
... Massey Cancer Center will open a Phase I ... with leading researchers from Israel, marking the first ... their counterparts in Israel. , The study ... U.S.-Israel Bi-National Industrial Research and Development Foundation (BIRDF). ...
... A free white paper is helping,building owners ... can result when they,re forced by the construction,schedule ... "system final,completion.", "There,s a disturbing trend in ... after occupancy," says Mike Della Barba,Director of Commissioning ...
... Social Security at http://www.nasi.org , WASHINGTON, March ... to comment on the implications of the,2008 Social Security ... listed below are members of the National Academy,of Social ... up of the nation,s leading,experts on Social Security, Medicare, ...
... Healthy,Coffee USA, Inc., the marketing arm of ... that Jim Clayton, a multi-level,marketing expert and start-up ... consultant. Mr. Clayton brings to the company a ... Clayton is a,start-up specialist who has been engaged ...
... of dying increased for patients with the common condition, ... Older people with heart failure face heightened odds of ... largest study ever conducted on the issue. , "We,re ... lead researcher Dr. Adrian F. Hernandez, an assistant professor ...
Cached Medicine News:Health News:Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer 2Health News:VCU Massey Cancer Center to partner with Israeli biotech firm 2Health News:VCU Massey Cancer Center to partner with Israeli biotech firm 3Health News:White Paper Helps Building Owners Avoid Costs, Downfalls of Construction Projects 2Health News:NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports 2Health News:NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports 3Health News:MLM Expert and Start-Up Specialist Jim Clayton Joins Healthy Coffee USA 2Health News:MLM Expert and Start-Up Specialist Jim Clayton Joins Healthy Coffee USA 3Health News:Heart Failure Raises Risks After Non-Cardiac Surgeries 2Health News:Heart Failure Raises Risks After Non-Cardiac Surgeries 3
... accurate portable, waterproof system for pH, mV (ORP), ... results can be obtained when used with a ... This GLP/GMP compliant system includes an RS-232 interface ... Up to 100 data sets can be stored ...
... 3 swing doors, 12 shelves. Over-sized compressor. ... Fluorescent interior lighting. Self-Contained System No plumbing ... Full One Year Warranty on Parts & ... Compressor. Also available as a chromatography ...
... shelves.Over-sized compressor. Triple pane thermal glass. ... System No plumbing required. Equipped with a ... on Parts & Labor and an Additional 4 ... as a chromatography unit which includes two access ...
... 1 swing door 4 shelves. ... Self-closing doors. Fluorescent interior lighting. Self-Contained ... 9 foot cord. Full One Year Warranty ... Year Warranty on Compressor. Also available ...
Medicine Products: